Close Menu
Fund Focus News
    Facebook X (Twitter) Instagram
    Trending
    • Bond Funds vs Individual Bonds Explained
    • How Mutual Funds Navigated Asset Classes Over The Past Year
    • Big Update For Mutual Fund Investors, SEBI’s New Circular Brings Fresh Rules That Could Directly Impact Your Returns
    • New mutual fund brokerage rules from April 1: How GST changes will affect distributors
    • Life Cycle Mutual Funds explained: SEBI’s new category with 5–30 year tenure
    • Volatile prices, high inflows take toll on gold, silver ETFs return
    • Sebi revamps mutual fund categories: Experts explain changes for investors | Personal Finance
    • Premium bonds: odds of a win to get worse from April | Savings
    Facebook X (Twitter) Instagram
    Fund Focus News
    • Home
    • Bonds
    • ETFs
    • Funds
    • Investments
    • Mutual Funds
    • Property Investments
    • SIP
    Fund Focus News
    Home»Funds»How Strategic Communication Seals The Deal
    Funds

    How Strategic Communication Seals The Deal

    September 5, 2025


    Kristine Johnson is the executive director and chief strategist at Cognition Studio.

    One of the most significant strategic challenges I see today—especially for early-stage founders—is calibrating the right balance between visionary ambition and operational credibility. Positioning a company for funding isn’t just about selling big. It’s about selling smart.

    When you’re in that first conversation with an investor, they want the big picture. They want to know: What’s the big idea? What’s your value proposition? That’s where you set the stage.

    But if you get to that second conversation, the focus shifts. It’s no longer just about your idea. Now, they want to know how you’re going to make it happen. It’s the “make me believe” stage. How do you actually create value through your product or service? How are you going to operationalize the vision?

    The mistake I see too often is overpromising. Many founders get excited and pitch beyond what they can realistically deliver. That’s a problem. If you over-pitch and under-deliver, investor trust crumbles. The skill of securing funding is in crafting a value proposition that shows ambition but is also rooted in what you can deliver today. Let’s talk about how to approach it.

    Strategic Communication Is How Vision Becomes Credible

    Strategic communication isn’t just an asset; it’s a differentiator. It’s the vehicle that transforms complex ideas into credible, investible narratives. When you’re going into a pitch, it’s not just about discussing a bunch of details. You have to be able to pace the information. From my observations, founders are often so immersed in their ideas that they forget to translate them for an outside perspective. That’s a costly blind spot in high-stakes conversations. They’re so immersed in the process that they forget the people they’re pitching to aren’t.

    Investors don’t need all the information at once. It’s a process. Your goal should be to present the right information at the right time. It takes time to build the story.

    In your first conversation, you’re educating them on the big idea. But by the second conversation, you’re converting interest into belief. Investors want to know: How are you different? Why does this matter? And in the third conversation, they’re communicating, “Okay, show me. Say I’m invested now, what does this partnership look like?”

    You’re not just pitching for money—you’re building the trust and credibility of a long-term partnership. Tesla is a great example of this. The company received criticism for its automation efforts in its Model 3 production. Elon Musk even acknowledged at one point: “Yes, excessive automation at Tesla was a mistake. To be precise, my mistake. Humans are underrated.” However, in my view, Tesla’s automation efforts showed ambition, as well as alignment between their bold vision and operational credibility. It was a preview of what Tesla would go on to do in the future.

    Scientific Pitches Must Show Progress Without Overpromising

    When we’re talking about new innovations, especially in health or medicine, it’s usually a much different type of conversation. Science is a slow process. It has to go through years of validation—clinical trials, FDA approvals—before you see any real impact.

    So when you’re pitching a scientific or medical innovation, the reality is that the actual patient impact could be 10 years down the road. That’s a challenge because investors want to know what’s happening now. How do you navigate that?

    It’s about explaining where you are today and why it matters. You have to show them the data. For medical startups, that might mean animal models or early trials. Investors need to see potential—addressable markets, unmet needs and what makes your solution different.

    But you can’t guarantee outcomes this early on. That’s where you have to be careful not to overpromise.

    Theranos founder Elizabeth Holmes and the single blood test scandal is a great example of what happens when you overpromise on science. Theranos became a case study in what happens when storytelling outpaces science. The lesson for today’s innovators is clear: Ambition must be anchored in evidence.

    Your focus should be on what you can realistically do today while making it clear how this technology could change in the future. Investors need to see both the potential and the practical steps you’re taking to get there.

    Why Patient-Centered Framing Turns Data Into Belief

    When you’re pitching something that’s going to impact patients, the story becomes even more important. It’s not just about the technology—it’s about the “why.” Why does this innovation exist? Is it replacing something? Is it disrupting the market? You need to explain why this matters in a way that connects with both the science and the human impact.

    For example, with radioisotopes used to treat cancer, most people would reasonably think, “Why would you put radioactive material in the body? Isn’t that dangerous?” But in the context of targeted cancer treatment, it’s exactly what you want—because it goes right where it needs to. That’s an example of the story investors need to understand. You’re not just talking about science, you’re explaining why this matters for the patients who will benefit from it.

    But again, you can’t overpromise. Just because a drug or technology works in early models doesn’t mean you can guarantee patient outcomes. What you need to do is focus on showing the data and demonstrating the potential. Explain the steps you’re taking today and how they’ll lead to that patient impact in the future.

    The whole process of securing funding is about telling the right story at the right time. You need to understand the value you’re creating and communicate that clearly. Whether you’re articulating a scientific breakthrough or positioning a commercial roadmap, the funding conversation is ultimately a test of strategic clarity. If you can match your message to the moment—balancing potential with proof—you’re not just pitching. You’re building the foundation for a partnership rooted in belief, trust and shared ambition.


    Forbes Business Council is the foremost growth and networking organization for business owners and leaders. Do I qualify?




    Source link

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email

    Related Posts

    SEBI broadens MF categories, introduces life cycle funds | Capital Market News

    February 26, 2026

    Fun run to raise funds for grieving Pembrokeshire children

    February 26, 2026

    India expands rules for $385 billion stock funds to add gold

    February 26, 2026
    Leave A Reply Cancel Reply

    Top Posts

    The Shifting Landscape of Art Investment and the Rise of Accessibility: The London Art Exchange

    September 11, 2023

    Bond Funds vs Individual Bonds Explained

    March 1, 2026

    Charlie Cobham: The Art Broker Extraordinaire Maximizing Returns for High Net Worth Clients

    February 12, 2024

    The Unyielding Resilience of the Art Market: A Historical and Contemporary Perspective

    November 19, 2023
    Don't Miss
    Bonds

    Bond Funds vs Individual Bonds Explained

    March 1, 2026

    1. What is the main difference between bond funds and individual bonds?Individual bonds have a…

    How Mutual Funds Navigated Asset Classes Over The Past Year

    February 28, 2026

    Big Update For Mutual Fund Investors, SEBI’s New Circular Brings Fresh Rules That Could Directly Impact Your Returns

    February 28, 2026

    New mutual fund brokerage rules from April 1: How GST changes will affect distributors

    February 28, 2026
    Stay In Touch
    • Facebook
    • Twitter
    • Pinterest
    • Instagram
    • YouTube
    • Vimeo
    EDITOR'S PICK

    Supreme Court strikes Osun’s suit on withheld local govt funds

    December 5, 2025

    2 ETFS and a FTSE 250 trust to consider from the London Stock Exchange

    October 12, 2025

    Why Schwab’s Outage Could Be The Best Thing For Your Portfolio

    August 5, 2024
    Our Picks

    Bond Funds vs Individual Bonds Explained

    March 1, 2026

    How Mutual Funds Navigated Asset Classes Over The Past Year

    February 28, 2026

    Big Update For Mutual Fund Investors, SEBI’s New Circular Brings Fresh Rules That Could Directly Impact Your Returns

    February 28, 2026
    Most Popular

    🔥Juve target Chukwuemeka, Inter raise funds, Elmas bid in play 🤑

    August 20, 2025

    💵 Libra responds after Flamengo takes legal action and ‘freezes’ funds

    September 26, 2025

    ₹10,000 monthly SIP in this mutual fund has grown to ₹1.52 crore in 22 years

    September 17, 2025
    © 2026 Fund Focus News
    • Get In Touch
    • Privacy Policy
    • Terms and Conditions

    Type above and press Enter to search. Press Esc to cancel.